Selvita is a product and solution provider for the pharmaceutical and biotechnology industry.
We are the first Polish biotech company with fully integrated drug discovery platform encompassing classical medicinal chemistry, in silico screening, structure-based drug design, molecular and cell biology, pharmacokinetics and pharmacology, as well as custom synthesis.
Selvita develops its own innovative drugs, which originate from research at Polish universities and later commercializes them with partners from the pharmaceutical industry. Selvita is involved in several research projects at the pre-clinical stage. Our current projects are in the area of oncology, central nervous system, and autoimmune disorders.
We employ over 120 top-class proffesionals from the area of medicine, chemistry, pharmacy, molecular biology, biotechnology and informatics, and 44 Selvita employees hold a PhD diploma in the field of biomedical research. Many of our experts have several years of experience in the biotechnology and pharmaceutical companies in the U.S., Canada, UK, Germany and Poland, and publications in the best scientific journals such as: Nature Biotechnology, Science, and the Journal of Medicinal Chemistry. We work with leading universities and research centers from Poland, Europe and United States.